Obesity is a current global epidemic that has led to a marked increase in metabolic diseases. However, its treatment remains a challenge. Obesity is a multifactorial disease, which involves the dysfunction of neuropeptides, hormones, and inflammatory adipokines from the brain, gut, and adipose tissue. An understanding of the mechanisms and signal interactions in the crosstalk between organs and tissue in the coordination of whole-body energy metabolism would be helpful to provide therapeutic and putative approaches to the treatment and prevention of obesity and related complications. Resveratrol and pterostilbene are well-known stilbenes that provide various potential benefits to human health. In particular, their potential anti-obesity effects have been proven in numerous cell culture and animal studies. Both compounds act to regulate energy intake, adipocyte life cycle and function, white adipose tissue (WAT) inflammation, energy expenditure, and gut microbiota by targeting multiple molecules and signaling pathways as an intervention for obesity. Although the efficacy of both compounds in humans requires further investigation with respect to their oral bioavailability, promising scientific findings have highlighted their potential as candidates for the treatment of obesity and the improvement of obesity-related metabolic diseases.
Introduction
More than two billion people are either overweight or obese, and the prevalence of obesity is still increasing sharply worldwide [1] . Obesity is considered a serious health problem, not only because of its influence on physical appearance but also its associations with various adverse health consequences. Although obesity is believed to be the result of interplay between genetic and non-genetic factors, much of the individual variation in obesity is accounted for by non-genetic factors, including diet, lifestyle, socio-cultural environment, and physiological condition; only a minor effect is attributed to genetics [2] . A prolonged period of imbalance between energy intake and expenditure, owing to a high caloric diet and lack of physical activity, stimulates the increased storage of energy in the form of triacylglycerols (TGs) in adipocytes, which leads to an increase in adipose tissue mass, body weight, and, eventually, to obesity. The pathogenesis and clinical presentations of obesity result from complex interactions between the adipose tissues, gastrointestinal (GI) system, central nervous system, peripheral nervous system, and gut microbiota; it is a multifactorial disease [3, 4] . An accumulation of evidence suggests that the communication among nutrients, neuropeptides, hormones, adipokines, and inflammatory mediators derived from specific organs, tissues, or cell types play important roles in the complicated pathogenesis of obesity [3] . The dysregulation of their crosstalk has a huge effect on energy homeostasis in adipose tissue, including cellular proliferation, differentiation, adipogenesis, and lipid and carbohydrate metabolism [3, 5] . Moreover, the low-grade chronic inflammation within adipose tissues participates in obesity-related complications such as insulin resistance and type 2 diabetes [6] . An understanding of the molecular mechanisms of the pathogenesis of obesity and the characterization of the interactions between adipose tissue and other organs provide insights and strategies for pharmacological and nutritional interventions.
The main challenge in the treatment of obesity arises because, once established, it is very difficult to reverse through interventions. Despite the wide recognition of lifestyle modifications, such as increased levels of physical activity and controlled diets, as the most effective approach for the management of obesity, a large number of individuals are unable to lose weight or even prevent the regain of body weight [7] . The current treatment options for obesity based on clinical guidelines include diet, exercise, cognitive behavior therapy, pharmacotherapy, and surgery [8] . Among these, pharmacotherapy is targeted toward the most overweight and obese subjects. These pharmacological drugs are designed to target multiple pathways involved in the regulation of energy balance, such as the decrease in energy intake (appetite-suppressant drugs, gastric, and pancreatic lipase inhibitors), the promotion of energy expenditure, and the modulation of adipocyte differentiation [5] . The efficacy of several anti-obesity drugs has been documented for the short-term management of obesity via oral methods alone or in combination with behavioral intervention. [9, 10] . Clinical studies have also shown that a combination of diverse pharmacological drugs represents a promising approach with different weight-loss properties [11] . However, the potential safety concerns and side effects of approved medications for the long-term management of obesity remain undetermined. In addition, although novel drug candidates and direct targets against obesity are currently under development, their benefit and long-term safety require further evaluation. Many studies have suggested that the use of natural products may be a potentially excellent strategy for the development of effective and safe anti-obesity agents. A variety of natural products such as flavonoids, curcuminoids, and stilbenoids from dietary and herbal plants exhibit beneficial effects on the prevention and treatment of obesity and its associated metabolic disorders [12] . The potential anti-obesity effects and their mechanism of action have been proposed, which are associated with the modulation of adipocyte life cycle, regulation of energy metabolism in adipocytes, appetite suppression, reduction in lipid absorption and energy intake, stimulation of thermogenesis, and modulation of gut microbiota [13] [14] [15] . Some of those natural products appear to exert beneficial effects through additive or synergistic interactions [16] . This review summarizes some of the recently reported knowledge of two stilbenoids, resveratrol and pterostilbene, in the prevention and management of obesity, and discusses their potential mechanisms of action.
An overview of resveratrol and pterostilbene
Stilbenes, which are natural phytochemicals with a low molecular weight (approximately 200-300 g/mol), are found widely in various plants, including medicinal plants, fruits, and vegetables, such as Polygonum cuspidatum, grapes, peanuts, and berries. Their chemical structure is characterized by the presence of a basic skeleton with a 1,2-diphenylethylene nucleus and a diverse range of modifications due to the pattern of hydroxylation, methoxylation, and polymerization [17] . Currently, more than 400 stilbenes have been identified, although their distribution in the plant kingdom is limited because the enzyme responsible for stilbene biosynthesis is not widely expressed [18] . Among them, resveratrol (3, 5, 4 0 -trihydroxytrans-stilbene), which was first identified in Polygonum cuspidatum, and also found in grapes, berries, peanuts, and jackfruit, is the most studied and well-characterized. A large body of evidence has demonstrated that resveratrol confers multiple beneficial effects for the prevention and treatment of various human diseases [19] . Most studies have suggested the three hydroxyl groups of resveratrol and the cis-or trans-structures are responsible for its biological properties [20] . Pterostilbene (3,5-dimethoxy-4 0 -hydroxy-trans-stilbene) is a methylated analog of resveratrol with two methoxy groups on the A ring and one hydroxyl group on the B ring. Pterostilbene has been identified in blueberries and grape products and has attracted
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much attention because of its chemopreventive and chemotherapeutic effects [21, 22] . The substitution of the hydroxy groups with methoxy groups is believed to increase the stability and lipophilicity of pterostilbene compared to those of resveratrol, which leads to better membrane permeability, cellular uptake, and bioavailability [21, 23] . The 3,5-dimethoxy motif on the A phenyl ring of pterostilbene is considered important for its pro-apoptotic activity in cancer cells [24] . Previous studies demonstrated that anti-obesity effect and mechanisms of action of both resveratrol and pterostilbene [25, 26] . Although markedly less research has been conducted on pterostilbene than on resveratrol and an extensive comparison has not been conducted, the structural differences between resveratrol and pterostilbene may account for their functional differences in the prevention and treatment of obesity and related metabolic syndromes.
3. Mechanisms of anti-obesity effect of resveratrol and pterostilbene
Modulation of food intake and nutrition absorption
The energy homeostasis in our bodies is organized by the signals from hypothalamic neuronal circuits, gut, adipose tissue, and other peripheral organs, which are contributing to regulating our appetite, feeding behavior, or satiety [27] . The complexity of these biological processes is tightly organized by a variety of neuropeptides, neurotransmitters, and hormones which are produced and secreted by central nervous system, peripheral nerves, GI tract, and other metabolic tissues [28] . These signals in the modulation of food intake provide a potential strategy for the development of anti-obesity drugs through the reduction of energy intake. The modulatory effect of resveratrol and pterostilbene on food intake has been investigated. In a non-human primate study, gray mouse lemurs (Microcebus murinus) fed with 200 mg/kg of resveratrol for 4 weeks showed reduced seasonal spontaneous obesity and food intake by 13%. Increased levels of glucose-dependent insulinotropic polypeptide (GIP), a gutderived hormone that promotes the mobilization of fat stores, were observed during resveratrol supplementation (from 104 6 14 pg/mL to 175 6 39 pg/mL). However, no significant change was found for other gut-derived satiety hormones by the intervention, including GLP-1, PP, and PYY. Despite this, resveratrol was shown to affect satiety through a reduction in spontaneous food intake in this primate [29] . In another in vivo study, male C57BL6/J mice intraperitoneally injected with 400 mg/kg resveratrol for 7 weeks showed an increase in the serum levels of GLP-1 of almost 20%. However, the authors did not conclude that the elevated serum GLP-1 was correlated with reduced body weight gain by resveratrol, but instead suggested it was able to improve the high-fat diet (HFD)-induced glycemic effect [30, 31] .
The inhibition of nutrient absorption has been proposed as an alternative approach for the treatment of obesity. The blockage of GI enzymes involved in carbohydrate and lipid metabolism may directly reduce their absorption. Studies have shown that resveratrol acts as an a-glucosidase inhibitor in the mammalian a-glucosidase activity and molecular docking assays [32, 33] . In HFD-fed male C57BL/6 mice, administered resveratrol inhibited a-glucosidase activity, which contributed to its ability to delay carbohydrates absorption in an oral carbohydrate challenge test, and thus resulted in a significant reduction of postprandial blood glucose [32] . Kim et al. compared the inhibition of pancreatic lipase by isolated stilbenoids from the roots of Vitis vinifera, and showed that the IC 50 value of resveratrol was more than 200 lM in comparison with the positive control, orlistat [34] . Despite this, the administration of 20 mg/kg resveratrol for 8 weeks reduced pancreatic lipase activity in the serum in rats fed a HFD by 55.6% and significantly enhanced fecal excretion of TGs, and thus assumed that resveratrol was acting via inhibition of pancreatic lipase which resulted in a lowered intestinal TG absorption and body weight [35] . These studies suggested that resveratrol may disrupt nutrient digestion and absorption, which reduces calorie intake from the diet.
Modulation of white adipocytes lifecycle
Two major types of adipose tissues, the white adipose tissue (WAT) and brown adipose tissue (BAT), are found in humans. White adipocytes are the primary cell type in WAT responsible for the storage of energy as fat. After excessive caloric intake, the expansion of WAT is characterized by two distinct mechanisms, adipocyte hypertrophy (cell size increase) and/or hyperplasia (cell number increase). Although two mechanisms participate in the enlargement of WAT mass, hypertrophy is attributed to the dysfunction of adipose tissue, which plays a role in the progression of metabolic disorders in obese subjects [36] . Targeting the adipocyte life cycle and its metabolic functions, such as the inhibition of proliferation, adipogenesis, and the stimulation of lipolysis and apoptosis in mature adipocytes, as well as the modulation of energy metabolism, should offer a promising approach for the prevention or treatment of obesity and related diseases [37] .
Despite the evidence illustrating that resveratrol is extensively metabolized by the phase II enzymes and accumulates in a relatively low concentration in tissues, the in vitro data remain valid due to rest of free resveratrol or retaining biological activity from its metabolites. Cellular studies have shown that it may regulate the adipocyte life cycle via multiple mechanisms including the inhibition of proliferation, differentiation, and adipogenesis, and the induction of apoptosis, lipolysis, and fatty acid oxidation [25, 38] . In 3T3-L1 preadipocytes, resveratrol suppressed adipogenesis through changes in the expression of several adipogenic transcription factors and enzymes, but induced apoptosis and reduced TNFa-induced lipolysis in mature adipocytes [39, 40] . Reduced adipocyte hypertrophy was also observed in obese men after the administration of resveratrol (150 mg) for 30 days (65.0 6 4.4 lm by resveratrol compared with placebo 74.7 6 3.5 lm), as evidenced by a reduction in the proportion of large and very large adipocytes and an increase in small adipocytes in subcutaneous adipose tissue [41] . Microarray analysis showed that resveratrol up-regulated gene expression of lysosomal pathway of lipid breakdown that may contribute to the decreased adipocyte size in obese men [41] . Resveratrol is a known SIRT1 activator, and was shown to stimulate fatty acid oxidation in mature 3T3-L1 adipocytes via the activation of SIRT1 [42] . Studies have concluded that resveratrol targets a variety of signaling molecules, transcription factors, and enzymes to exert different modulatory effects on the adipocyte life cycle and metabolic functions [25] .
Several studies have also documented the regulatory effect of pterostilbene in adipocytes and WAT. The targeting of mitotic clonal expansion at the early stage of adipocyte differentiation could be the potential mechanism through which pterostilbene exerts its anti-obesity effect. Hsu et al. showed that pterostilbene reduced cell proliferation and induced cell cycle arrest at the G2/M phase in 3T3-L1 preadipocytes, and inhibited adipocyte differentiation and lipid accumulation through the attenuation of adipogenic factors [43] . Seo et al. reported that pterostilbene interfered with the MCE of adipocytes through the upregulation of HO-1-mediated CHOP10 expression, resulting in an increase in C/EBPb levels and cell cycle arrest, which in turn blocked terminal differentiation. This study also suggested that HO-1 acted as a negative regulator of adipocyte differentiation and indicated potential molecular target for the anti-obesity effect of pterostilbene [44] . In animal studies, pterostilbene was found to combat dietinduced obesity predominantly through enhanced energy expenditure, which was supported by an increase in lipid oxidation and uncoupling protein in WAT from obese OLETF rats [45] , and reduced lipogenesis in adipose tissue from dietinduced obese rats [46] . A comparison of pterostilbene and resveratrol on lipolysis and lipogenesis was conducted in mouse and human adipocytes. Gomez-Zorita et al. reported that pterostilbene inhibited glucose incorporation into lipids in mature adipocytes in a similar manner to that by resveratrol, but did not contribute to the reduced glucose uptake mediated by resveratrol. These results suggested that the anti-lipogenic effect of pterostilbene was most likely to occur through interference in the processes of fatty acid synthesis from glucose, such as hexokinase phosphorylation, pyruvate generation, and acetyl-CoA conversion [47] .
Modulation of inflammation in WAT
WAT is recognized as an endocrine organ that is implicated in energy homeostasis via the secretion of various adipokines, cytokines, growth factors, and hormones. In response to a positive energy balance, preadipocytes undergo adipogenesis, which leads to excessive fat accumulation and subsequently expanded adipose tissue. The increased metabolic activity of adipocytes in the progression of obesity also produces inflammatory adipokines, such as IL-6, TNF-a, MCP-1, and CRP, to trigger the infiltration of immune cells that creates a chronic low-grade inflammation in enlarged WAT [36] . The enhanced chronic inflammatory state caused by the accumulation of adipose tissue macrophages (ATMs) has an effect on the metabolic homeostasis of WAT and is also implicated in the initiation of obesity-related insulin resistance [48] The disruption of the overproduction of pro-inflammatory adipokines, inflammatory signaling, and the crosstalk between adipocytes and macrophages might be attractive targets in the prevention and treatment of obesity and the improvement of metabolic syndromes [6, 49] .
The anti-inflammatory effect of resveratrol has been proposed in numerous studies. Kim et al. reported that dietary resveratrol attenuated HFD-induced adipogenesis and inflammation in the epididymal fat tissues of mice. The levels of proinflammatory cytokines in adipose tissue were downregulated by resveratrol, which may have occurred through the interruption of upstream TLR2-and TLR4 signaling [50] . In obese mice treated with resveratrol, the elevated levels of IL-6, MCP-1, and TNF-a in adipose tissue were reduced. Moreover, resveratrol induced the marker genes of M2 macrophages (alternatively activated macrophages), whereas the genes of M1 macrophages (classically activated macrophages) were decreased, which indicated that resveratrol could induce the macrophage switch in WAT [51] . Indeed, resveratrol has been shown to reduce inflammation through the disruption of the crosstalk between adipocytes and macrophages, which occurs via a decrease in pro-inflammatory cytokines and the suppression of inflammatory signaling, in an experimental model using macrophage-conditioned medium or macrophage coculture [52] [53] [54] . The aforementioned studies indicate the therapeutic effect of resveratrol in obesity-associated WAT inflammation occurred through the targeting of the crosstalk between adipocytes and ATMs.
The effect of pterostilbene on proinflammatory responses and interactions between 3T3-L1 adipocytes and RAW 264.7 macrophages was also reported. In TNF-a-treated 3T3-L1 adipocytes, pterostilbene significantly decreased the gene expression of proinflammatory cytokines and IL-6 secretion. Pterostilbene also disrupted the migration of macrophages toward adipocytes via interference in IL-6 and TNF-a secretion in a coculture model. In addition, pterostilbene reduced IL-6 and TNF-a secretion in both adipocytes and macrophages that were treated in macrophage-and adipocyte-derived conditioned medium, respectively. This study proposed the modulatory action of pterostilbene on WAT inflammation by targeting the interaction between adipocytes and macrophages via the blockage of proinflammatory cytokine production and interference in inflammatory signaling [55] . Although an insulinimproving effect of pterostilbene in WAT has not yet been reported, two animal studies have shown that the diet-induced dysregulated serum insulin level and HOMA-IR were improved by pterostilbene [46, 56] . G omez-Zorita et al. suggested that dietary pterostilbene (10 mg/kg) improved insulin resistance and glucose uptake in the muscles and the liver of rats fed an obesogenic diet. The authors proposed that the anti-diabetic molecular mechanism of pterostilbene occurred through an increase in hepatic glucokinase activity and GLUT4 in skeletal muscle, but may also be associated with its anti-inflammatory effect owing to the elevated level of cardiotrophin-1, an antiinflammatory cytokine [56] . Both resveratrol and pterostilbene modulated proinflammatory adipokines expression which relative to inhibition of adipocyte-macrophage crosstalk in WAT, whereas resveratrol also regulated ATM polarization that contributing to its anti-inflammatory mechanism for obesityassociated inflammation.
Modulation of mitochondrial function in white adipocyte
Mitochondria are the major source of ATP production in cells, including white adipocytes. The mitochondrial content, biogenesis, turnover, and dynamic remodeling all play a pivotal role in white adipocyte differentiation and metabolic function. Mitochondrial dysfunction caused by oxidative damage, lipotoxic effect, and proinflammatory cytokines as a result of high energy demand impairs cellular functions such as differentiation, adipogenesis, oxidative capacity, insulin sensitivity, and lipid homeostasis in adipocytes, and may even contribute to systemic metabolic disruption [57] . The targeting of mitochondrial function in white adipocytes has been proposed as a therapeutic strategy for the treatment of obesity [57, 58] . Many in vitro and in vivo studies have addressed the action of resveratrol against adipogenesis in preadipocytes through the modulation of mitochondrial mass, biogenesis, and remodeling (fusion and fission) through the modification of gene expression, respiratory chain complexes, or ROS signaling [58] . In mature adipocytes, resveratrol appears to reduce lipid content via the elevation of mitochondrial activity [59] . Resveratrol also exerts an ATP-depleting effect through the attenuation of the hyperpolarization of the inner mitochondrial membrane in rat adipocytes and the subsequent interruption of mitochondrial metabolism that is evidenced by a reduction in oxidative capacity. The molecular targets through which resveratrol modulates mitochondrial function in white adipocytes has concluded that it interacts with SIRT1 and directly interacts with respiratory chain complexes such as Complex I and F0F1 ATP synthase in other cells and organs [60, 61] .
Induction of thermogenesis
BAT is the other major type of adipose tissue in the human body, and has a distinct biological function to that of WAT. BAT is characterized by multilocular lipid droplets and is essential for the maintenance of body temperature in rodents and human infants through the conversion of energy to generate heat (thermogenesis) [62] . The capacity of BAT to dissipate energy is attributed to the increased number of mitochondria in brown adipocytes that contain an abundance of the specialized inner membrane mitochondrial protein, uncoupling protein 1 (UCP1) [63] . Only a small amount of BAT is found in adult humans, although several recent studies have confirmed the dispersion of active BAT in the cervical, supraclavicular, mediastinal, paravertebral, and suprarenal regions from adult humans [64] . The rediscovery of functional BAT in humans provides an exciting platform for the development of pharmacological agents through either an increase in BAT thermogenesis (via an increase of mass and activity) or the induction of brown fat-like properties in WAT to dissipate energy, and hence reduce obesity [65] . Oral administration of resveratrol in mice fed a standard diet enhanced thermogenesis that was associated with the increased expression of UCP1, SIRT1, and AMPK in BAT, which facilitate a higher expenditure of energy [66] . In addition to the enhanced thermogenesis in BAT, resveratrol induced brown fat-like properties in primary stromal vascular cells isolated from interscapular BAT, followed by elevated UCP1, PRDM16, and PGC-1a, as well as increased oxygen consumption [67] . The induction of browning by resveratrol was also observed in HFD-fed mice in the same study. The mice administered resveratrol showed the induction of expression of genes specific to brown adipocytes in interscapular BAT, in addition to the appearance of multilocular adipocytes, which are characteristic of brown adipocytes [67] . These data suggested a potential role for resveratrol in thermogenesis through the enhancement of BAT function and the induction of browning, which may provide another novel strategy for the prevention and treatment of obesity and related diseases in addition to the inhibition of adipogenesis and the stimulation of lipolysis. Only a single study has investigated the effect of pterostilbene on BAT. Zucker rats orally administered pterostilbene (15 and 30 mg/kg) showed reduced body weight and WAT adiposity, whereas no change was observed in BAT mass. The expression of brown adipocyte-specific genes, including UCP1, PPARa, and NRF1, were upregulated in BAT in addition to increases in the enzyme activity of CPT1b and citrate synthase. These results indicated the role of pterostilbene in the promotion of the thermogenic and oxidative capacity of BAT in obese rats [68] .
Modulation of gut microbiota
Recent studies have highlighted the important role of gut microbiota in obesity and metabolic disorders [69] . Diet, disease, medication, the environment, and the host genetic background all contribute to changes in the composition of gut microbiota. The exact mechanisms that link gut microbiota to obesity remain obscure; it may be explained by the effects on calorie harvest and energy homeostasis, increased fatty acid metabolism, alteration of fatty acid composition in adipose tissue, the stimulation of low-grade inflammation, and the modification of gut-derived peptide secretion [70, 71] . Human and animal studies have demonstrated a shift in the gut microbial composition with obesity that was mostly influenced by diet. The experimental data suggested that gut microbiota manipulation through dietary intervention may be beneficial for the treatment of obesity [72, 73] . In HFD-fed mice, dietary resveratrol (200 mg/kg) was shown to regulate the composition of gut microbes, as noted by increased Bacteroidetes-to-Firmicutes ratios, increased growth of Lactobacillus and Bifidobacterium, which was correlated to the reduction in body weight. Moreover, a correlation was found between reduced Lactococcus, Clostridium XI, Oscillibacter, Hydrogenoanaerobacterium, and lowered biomarkers for metabolic syndrome (WAT, glucose homeostasis, and intestinal inflammation) caused by resveratrol [74, 75] . Furthermore, another in vivo study showed that the reduced body weight gain was found by resveratrol administration in Wistar rats fed a high-fat sucrose diet whereas no profound effects on gut microbiota composition were identified [76] . The contrasting results obtained in the above studies may be attributed to differences in animal species, the composition of diet, and the dosage of resveratrol. Pterostilbene supplementation also displayed a modulatory effect on obesityassociated dysbiosis of the gut microbiota. Zucker (fa/fa) rats administrated pterostilbene (15 mg/kg) showed improved insulin sensitivity and reductions in body weight and serum cholesterol. The shift in gut microbiota composition in obese rats was modified by pterostilbene, resulting in a decrease in Firmicutes and an increase in Verrucomicrobia phyla. Particularly, the cholesterol-lowering effect of pterostilbene was associated with an enrichment of the Verrucomicrobia phylum [77] .
Bioavailability of resveratrol and pterostilbene
Despite the current findings, the clinical application of resveratrol for the treatment of obesity remains a challenging owing to its low bioavailability. Resveratrol is highly photosensitive, unstable, and rapidly and extensively metabolized in the intestine and liver, which leads to low bioavailability, even though several human studies have shown that a higher dose (a 500 mg single oral dose) of resveratrol was well tolerated [78] . The very low bioavailability of resveratrol is because of it is rapidly and extensively metabolized in vivo [79] . The plasma level of resveratrol measured in human or rodent following oral administration range from high nanomolar to a few micromolar. In a human study, less than 5 ng/mL of free resveratrol could be detected in plasma via a dietary relevant 25 mg oral dose [80] , but was elevated to about 71.2 ng/mL following a single 500 mg oral dose [78] . Extremely rapid sulfate and glucuronide conjugation of resveratrol by the Phase II enzymes in the intestine and liver appears to be the limiting step for its bioavailability [79, 80] . Several approaches have Proposed molecular mechanisms underlying the anti-obesity effect by resveratrol and pterostilbene through regulation of energy intake, adipocyte lifecycle and function, WAT inflammation, energy expenditure, and gut microbiota. been proposed to increase the bioavailability of resveratrol by improving its delivery and uptake, such as consumption with various foods, precursors/pro-drugs, controlled release devices, and nanotechnological formulations [81] . In contrast, the dimethyl ether structure of pterostilbene is believed to be more stable and able to generate more lipophilicity than resveratrol, which leads to reduced metabolism and better bioavailability [82, 83] . Rats orally administered with 50 or 150 mg/kg/day of resveratrol and 56 or 168 mg/kg/day of pterostilbene for 14 consecutive days displayed a greater bioavailability of pterostilbene with 80% oral bioavailability in comparison to only 20% for resveratrol, which evidenced by elevated total plasma levels of both the parent compound and metabolites than those of resveratrol [82] . Although pterostilbene has similar pharmacological properties to those of resveratrol, studies have shown its higher potency in the reduction of DNA damage, cognitive improvements, and anti-colon tumorigenesis [84] [85] [86] [87] . One potential explanation proposed for the greater efficacy of pterostilbene is related to the substitution of the hydroxy group of resveratrol with a methoxy group, which generates better circulation for subsequent bioaccumulation at the target organ [86] . Human clinical trials have suggested that pterostilbene is generally safe for use in humans up to 250 mg/day [88] ; however, little is known about its bioavailability and anti-obesity effect in the human body.
Conclusion
Over the past few decades, nutritional interventions based on the use of dietary natural products have emerged as a promising approach for the prevention and treatment of obesity and related complications because of their presence in commonly consumed foods. Stilbenes such as resveratrol and pterostilbene have received particular interest owing to their extensive biological activities. Numerous in vitro cell culture studies and in vivo animal studies have revealed that these two stilbenes exert potential efficacy against obesity and beneficial effects on energy homeostasis. Both resveratrol and pterostilbene are shown to act through more than one of the mechanisms involved in the regulation of energy intake, adipocyte lifecycle and function, WAT inflammation, energy expenditure, and gut microbiota; these compounds target multiple signaling pathways, transcription factors, proteins, and enzymes ( Fig. 1 and Table 1 ). Importantly, resveratrol and pterostilbene not only reduced adiposity in WAT but also induce thermogenesis in both WAT and BAT. One potential explanation proposed for the greater efficacy of pterostilbene is related to the substitution of the hydroxy group of resveratrol with a methoxy group, which generates better circulation for subsequent bioaccumulation at the target organ [86] . Another explanation is that the mode of action and molecular targets (such as PPARa and androgen receptor) of pterostilbene differ from those of resveratrol [47, 86, 89] . The current bioavailability research of resveratrol and pterostilbene remains much uncertainty, which may due to different quantification methods and formulations used in various in vivo studies. Therefore, it is difficult to identify a relevant physiological dosage of them with beneficial effects for human health. Establish a standard analyzed method as a reference is required to investigate the bioavailability of resveratrol, pterostilbene and their different formulations. In addition, further clinical studies are in progress to investigate the safety, benefits, and therapeutic targets involved in the energy homeostasis of resveratrol and pterostilbene. The improvement of bioavailability of the combination of resveratrol and pterostilbene, or other natural products based on different molecular targets, might result in synergistic or enhanced efficacy for the treatment of obesity and related complications.
